Atorvastatin for reduction of 28-day mortality in severe and critical COVID-19 patients: a randomized controlled trial
Abstract Background COVID-19 is an abnormal host response to the SARS-CoV-2 infection, which is associated with endothelial dysfunction and multi-organ failure. Atorvastatin has been proposed to reduce COVID-19 severity and mortality in chronic and de-novo users. Methods This randomized double-blind...
Main Authors: | Naglaa Hamdi Eltahan, Neamat Hamdy Elsawy, Kholoud M. Abdelaaty, Amal Salah Elhamaky, Ahmed H. Hassan, Moataz Maher Emara |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2024-02-01
|
Series: | Respiratory Research |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12931-024-02732-2 |
Similar Items
-
Atorvastatin for reduction of 28-day mortality in hospitalized COVID-19 patients: study protocol for a randomized, double-blinded, placebo-controlled, clinical trial
by: Moataz Maher Emara, et al.
Published: (2022-08-01) -
Development and validation of a simple method for the determination of Atorvastatin calcium in pure and pharmaceutical formulations using spectrofluorimetry
by: Nisreen Ahmad, et al.
Published: (2023-03-01) -
The effect of the various doses of atorvastatin on renal tubular cells; an experimental study
by: Hamid Nasri, et al.
Published: (2016-07-01) -
Comparative efficacy and safety among high-intensity statins. Systematic Review and Meta-Analysis
by: Myriam Jaam, et al.
Published: (2023-02-01) -
Are statins toxic or safe for kidney diseases? An updated mini-review study
by: Shadi Botshekan, et al.
Published: (2020-10-01)